Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2008. Revenue for the third quarter was $197,000, compared with revenue of $230,000 for the third quarter of 2007.

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida.

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.

Aradigm Investor Relations, 510-265-8850/9370 or Lippert/Heilshorn & Associates Don Markley or Bruce Voss, 310-691-7100 Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or "Company"), a specialty pharmaceutical company, today announced that Novo Nordisk ("Novo") transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008.

Aradigm Corporation (OTCBB: ARDM) (the "Company"), a specialty pharmaceutical company, today announced it will hold a business update conference call on Wednesday, July 16, 2008 at 11:00 a.m. Eastern (8:00 a.m. Pacific).